| This week's sponsor is FierceBiotech Drug Development Forum. | | | FierceBiotech 2nd Drug Development Forum - September 25-27 in Boston
90+ executive-level speakers share advanced partnership and pipeline strategies. Learn to adapt to increased deal complexity, real world evidence and digital technologies. Unequaled networking! Sign up by August 11 to save $200 on registration. |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Thursday, August 3, 2017 Bristol-Myers Squibb will pay $300 million up front and up to $2 billion in biobucks for IFM Therapeutics and its new immuno-oncology approaches. |
|
|
Top Stories Of The Week Friday, August 4, 2017 Gilead Sciences, under intense investor pressure to do a significant M&A deal, may have found a target it likes. It is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others. Friday, August 4, 2017 Parkinson’s patients treated with an approved diabetes drug did better on movement tests than did patients who received a placebo, University College London researchers found. If they can prove the drug changes the disease itself, it could transform the way we treat Parkinson’s. Thursday, August 3, 2017 Get set for even more competition in the hepatitis C space. AbbVie’s Mavyret picked up FDA approval on Thursday as an 8-week treatment regardless of genotype, becoming the first such drug with the indication. Monday, August 7, 2017 MyoKardia just announced that its experimental drug mavacamten improved heart function in patients with an inherited cardiac condition, with 8 of 10 showing normal readings after treatment with the drug. Monday, August 7, 2017 What’s the best pharma market in the world? Allergan CEO Brent Saunders figures it's no contest. During last week’s second-quarter earnings call, he gave the title to medical aesthetics, an area where the Botox maker is leading—and growing fast. Monday, August 7, 2017 Fresenius Medical Care is set to buy NxStage Medical for about $2 billion. The takeover will bolster Fresenius’ presence in the at-home dialysis market, positioning it to continue profiting if patients opt against receiving treatment in its care centers. Wednesday, August 9, 2017 Pfizer committed to building a $100 million gene therapies plant in North Carolina and in exchange, North Carolina committed to providing the drugmaker with a quarter-million dollars' worth of help. Tuesday, August 8, 2017 PRA Health Sciences is shelling out $530 million upfront to purchase health data and analytics expert Symphony Health, just as it reports double-digit service revenue growth for the 11th quarter consecutively since it went public in late 2014. Monday, August 7, 2017 Sanofi Pasteur has brought online a new quality testing facility at its Pennsylvania campus, which will play a pivotal role in ramping up flu vaccine production. |
